McBeath Joins Slade Health in NSW

McBeath including its TGA licenced compounding business, has now formally joined Slade Health as part of Icon’s acquisition of McBeath Health Services.

Together, Slade and McBeath are committed to delivering the highest standard of specialist patient care and excellence in compounding and pharmacy services to their customers in NSW.

Service and supply arrangements currently provided to hospitals will continue as normal with the McBeath pharmacy team now being located at Mt Kuring-Gai.

According to Slade Managing Director, David Slade, this furthers expands Slade’s compounding capabilities and presence in the market across the east coast, particularly in NSW.

This is an exciting time and great opportunity for Slade”, David said. “McBeath has a strong presence in the NSW/ACT market and significant customer relationships. The McBeath business has great experience in chemotherapy supply and the management of PBS services to hospitals. We look forward to welcoming Adrian Wilson and his team.”

The McBeath merger follows the Slade acquisition of the Fresenius Kabi compounding facilities in October which increased the Slade Health TGA licenced facilities to four across Australia

If you require further information please feel free to contact:

*         Adrian Wilson, CEO, Slade Pharmacy
*         Paula Clark, Executive Director, Sales and Marketing, Slade Health
*         David Slade, CEO & Director, Slade Health

Visit our contact us page for our office details.